Maximilian Diehn

Maximilian Diehn at Stanford developed CAPP-Seq, a highly sensitive targeted sequencing approach for ctDNA detection in lung cancer and lymphoma. His laboratory pioneered fragmentomics-based cancer detection using cell-free DNA size and fragmentation patterns. He has translated ctDNA MRD monitoring into radiation oncology settings, demonstrating that post-treatment ctDNA predicts relapse after curative-intent radiotherapy.